Literature DB >> 17785728

Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.

Omid S Tehrani1, Otto Muzik, Lance K Heilbrun, Kirk A Douglas, Jawana M Lawhorn-Crews, Haihao Sun, Thomas J Mangner, Anthony F Shields.   

Abstract

UNLABELLED: The kinetics of 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)thymine (FMAU) were studied using PET to determine the most appropriate and simplest approach to image acquisition and analysis. The concept of tumor retention ratio (TRR) is introduced and validated.
METHODS: Ten patients with brain (n = 4) or prostate (n = 6) tumors were imaged using (18)F-FMAU PET (mean dose, 369 MBq). Sixty-minute dynamic images were obtained; this was followed by whole-body images. Mean and maximum standardized uptake values (SUVmean and SUVmax, respectively) of each tumor were determined as the mean over 3 planes of each time interval. For kinetic analyses, blood activity was measured in 18 samples over 60 min. Samples were analyzed by high-performance liquid chromatography at 3 selected times to determine tracer metabolites. FMAU kinetics were measured using a 3-compartment model yielding the flux (K1 x k3/(k2 + k3)) (K1, k2, and k3 are rate constants) and compared with TRR measurements. TRR was calculated as the tumor (18)F-FMAU uptake area under the curve divided by the product of blood (18)F-FMAU AUC and time. A similar analysis was performed using muscle to estimate (18)F-FMAU delivery.
RESULTS: SUVmean measurements obtained from 5 to 11 min correlated with those obtained from 30 to 60 min (r(2) = 0.92, P < 0.0001) and 50 to 60 min (r(2) = 0.92, P < 0.0001) due to the rapid clearance of (18)F-FMAU. Similar results were obtained using SUVmax measurements (r(2) = 0.93, P < 0.0001; r(2) = 0.88, P < 0.0001, respectively). The measurement of TRR using either blood or muscle activity over 11 min provided results comparable to those of 60-min dynamic imaging and a 3-compartment model. This analysis required only 5 blood samples drawn at 1, 2, 3, 5, and 11 min without metabolite correction to produce comparable results.
CONCLUSION: Tissue retention ratio measurements obtained over 11 min can replace flux measurements in (18)F-FMAU imaging. The SUVmean and the SUVmax in 5-11 min images correlated well with those of images obtained at 50-60 min. The quality of the images and tissue kinetics in 11 min of imaging makes it a desirable and shorter tumor imaging option.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785728     DOI: 10.2967/jnumed.107.042762

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples.

Authors:  Vincenzo Paolillo; Hsin Hsien Yeh; Uday Mukhopadhyay; Juri G Gelovani; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2011-07-08       Impact factor: 2.408

5.  Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer.

Authors:  Weiwei Fan; Zhiwei Zhang; Zheng Zhu; Deyong Yang; Xiaochi Chen; Jianbo Wang; Feng Chen; Xishuang Song
Journal:  Oncol Lett       Date:  2015-08-19       Impact factor: 2.967

6.  PET/CT in prostate cancer: non-choline radiopharmaceuticals.

Authors:  P Castellucci; H Jadvar
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-08       Impact factor: 2.346

7.  Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer.

Authors:  Bino Varghese; Erik Velez; Bhushan Desai; Hossein Jadvar
Journal:  Clin Nucl Med       Date:  2018-07       Impact factor: 7.794

8.  An investigation on stereospecific fluorination at the 2'-arabino-position of a pyrimidine nucleoside: radiosynthesis of 2'-deoxy-2'-[(18)F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil.

Authors:  Nashaat Turkman; Vincenzo Paolillo; Juri G Gelovani; Mian M Alauddin
Journal:  Tetrahedron       Date:  2012-12-16       Impact factor: 2.457

Review 9.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

10.  A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.

Authors:  Ulka N Vaishampayan; Omid S Tehrani; Jawana M Lawhorn-Crews; Lance K Heilbrun; Kimberlee Dobson; Daryn Smith; Brenda Dickow; Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.